Comparability protocol for 22.5 MG tablets (nada # 141-526)
Ended Project Grant Awarded Last action
- Award ID
- R01FD007800
- Recipient
-
Anivive Lifesciences Inc. UEI HR9KVMTD5467
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $214,100
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Funding agency
- Center for Veterinary Medicine Food and Drug Administration, Department of Health and Human Services
- Place of performance
- New Jersey, USA
Award details come from USAspending.gov.
Description
- Abstract
- The protocol is to add an additional strength of laverdia tablets. Successful execution of this protocol will result in the addition of a 22.5 MG tablet to the existing portfolio of 2.5 MG, 10 MG and 50 MG tablets. There will be no changes to the manufacturing process or facility currently approved for laverdia tablets. Approved analytical procedures will be used to assess and test the new tablet strength.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | -$64,360 | |
| Amendment | -$64,360 | |
| Amendment | -$157,180 | |
| Amendment | $250,000 | |
| Original award | $250,000 |
Quick answers
Who received award R01FD007800?
R01FD007800 was awarded to Anivive Lifesciences Inc. by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on December 1, 2022.
How much is award R01FD007800 worth?
$214,100 has been obligated on R01FD007800.
Which agency awarded R01FD007800?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD007800, with funding from Center for Veterinary Medicine (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award